Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.04
BSPM's Cash to Debt is ranked lower than
97% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.99 vs. BSPM: 0.04 )
Ranked among companies with meaningful Cash to Debt only.
BSPM' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 32.03 Max: No Debt
Current: 0.04
Equity to Asset 0.87
BSPM's Equity to Asset is ranked higher than
89% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. BSPM: 0.87 )
Ranked among companies with meaningful Equity to Asset only.
BSPM' s Equity to Asset Range Over the Past 10 Years
Min: 0.79  Med: 0.88 Max: 0.96
Current: 0.87
0.79
0.96
F-Score: 4
Z-Score: -0.25
M-Score: -5.00
WACC vs ROIC
18.40%
-40.20%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -111.95
BSPM's Operating margin (%) is ranked lower than
89% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.72 vs. BSPM: -111.95 )
Ranked among companies with meaningful Operating margin (%) only.
BSPM' s Operating margin (%) Range Over the Past 10 Years
Min: -87.57  Med: 19.75 Max: 30.5
Current: -111.95
-87.57
30.5
Net-margin (%) -121.64
BSPM's Net-margin (%) is ranked lower than
90% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.96 vs. BSPM: -121.64 )
Ranked among companies with meaningful Net-margin (%) only.
BSPM' s Net-margin (%) Range Over the Past 10 Years
Min: -92.57  Med: 13.24 Max: 24.95
Current: -121.64
-92.57
24.95
ROE (%) -42.47
BSPM's ROE (%) is ranked lower than
87% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.03 vs. BSPM: -42.47 )
Ranked among companies with meaningful ROE (%) only.
BSPM' s ROE (%) Range Over the Past 10 Years
Min: -43.08  Med: 17.78 Max: 34.28
Current: -42.47
-43.08
34.28
ROA (%) -37.28
BSPM's ROA (%) is ranked lower than
88% of the 773 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.68 vs. BSPM: -37.28 )
Ranked among companies with meaningful ROA (%) only.
BSPM' s ROA (%) Range Over the Past 10 Years
Min: -37.87  Med: 16.11 Max: 30.2
Current: -37.28
-37.87
30.2
ROC (Joel Greenblatt) (%) -71.96
BSPM's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 762 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.24 vs. BSPM: -71.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BSPM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -74.36  Med: 50.12 Max: 96.91
Current: -71.96
-74.36
96.91
Revenue Growth (3Y)(%) -30.20
BSPM's Revenue Growth (3Y)(%) is ranked lower than
93% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. BSPM: -30.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BSPM' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.2  Med: -13.6 Max: 56.5
Current: -30.2
-30.2
56.5
EBITDA Growth (3Y)(%) -12.70
BSPM's EBITDA Growth (3Y)(%) is ranked lower than
81% of the 555 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.00 vs. BSPM: -12.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BSPM' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -45.6  Med: -12.7 Max: 49.8
Current: -12.7
-45.6
49.8
EPS Growth (3Y)(%) -8.00
BSPM's EPS Growth (3Y)(%) is ranked lower than
70% of the 520 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.20 vs. BSPM: -8.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BSPM' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.7  Med: -8 Max: 49.1
Current: -8
-66.7
49.1
» BSPM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

BSPM Guru Trades in Q3 2015

Jim Simons 695,570 sh (+2.31%)
» More
Q4 2015

BSPM Guru Trades in Q4 2015

Jim Simons 707,370 sh (-85.47%)
» More
Q1 2016

BSPM Guru Trades in Q1 2016

Jim Simons 104,856 sh (+3.76%)
» More
Q2 2016

BSPM Guru Trades in Q2 2016

Jim Simons 105,956 sh (+1.05%)
» More
» Details

Insider Trades

Latest Guru Trades with BSPM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:OTCPK:ECTE, AMEX:CPHI, OTCPK:INBP, NAS:IMNP, OTCPK:CHEXF, OTCPK:SUWN, NAS:ALQA, NAS:PRPH, OTCPK:INNV, AMEX:AXN, NAS:TNXP, NAS:ALIM, OTCPK:BIOYF, AMEX:NNVC, NAS:ASMB, NAS:OASM, NAS:NBRV, NAS:ZGNX, NAS:BITI, NAS:RMTI » details
Traded in other countries:7BNB.Germany,
Biostar Pharmaceuticals Inc, through its subsidiaries is engaged in the business of developing, manufacturing and marketing over-the-counter and prescription pharmaceutical products in the Peoples Republic of China.

Biostar Pharmaceuticals Inc is a Maryland corporation incorporated on March 27, 2007. It is a holding company that through its wholly-owned subsidiary Shaanxi Biostar Biotech, Ltd. and its variable interest entities Shaanxi Aoxing Pharmaceutical Co., Ltd., and Shaanxi Weinan Aoxing Pharmaceuticals, LLC develops, manufactures and markets pharmaceutical products for a variety of diseases and conditions in the Peoples Republic of China. Its popular product is Xin Ao Xing Oleanolic Acid Capsule, an over-the- counter (OTC) medicine for chronic hepatitis B. Its product line also includes five other OTC products, ten prescription-based pharmaceuticals, six nutriceuticals or health products and one medical device. The Company's products are derived from medicinal herbs that are either grown at its own facility or purchased from its suppliers. It has currently eight products under development to complement its existing product line. It has adopted international manufacturing standards and currently holds one patent, with two additional patents pending approval. The Company's products are currently being sold in over 25 provinces in the PRC through 25 distributors and an established network of more than 400 dedicated sales people. The Company's competitors includes, Wulanhaote Zhong Meng pharmaceutical Co., Ltd., Yang Ling Mai Di Sen Pharmaceutical Co., Ltd, Jiang Xi Ren He Pharmaceuticals, Inc; Hainan Asia Pharmaceuticals, Inc; Nan Yong An Pharmaceuticals, Inc; Hai Nan Min Hai Pharmaceuticals, Ltd; Shandong Bai Cao Pharmaceuticals, Ltd; Chang Chun Ren Min Pharmaceuticals, Ltd; Yun Nan Yu Xi City Wei He Pharmaceutical, Ltd; Shandong Phoenix Pharmaceuticals, Ltd; Wulanhaote Zhong Meng Pharmaceutical Co., Ltd; Yang Ling Mai Di Sen Pharmaceutical Co., Ltd; and other traditional Chinese medicine suppliers. The Company' operations and facilities are subject to environmental laws and regulations stipulated by the national and the local environment protection bureaus in the PRC.

Ratios

vs
industry
vs
history
P/B 0.14
BSPM's P/B is ranked higher than
98% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. BSPM: 0.14 )
Ranked among companies with meaningful P/B only.
BSPM' s P/B Range Over the Past 10 Years
Min: 0.06  Med: 0.28 Max: 3.04
Current: 0.14
0.06
3.04
P/S 0.30
BSPM's P/S is ranked higher than
93% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.72 vs. BSPM: 0.30 )
Ranked among companies with meaningful P/S only.
BSPM' s P/S Range Over the Past 10 Years
Min: 0.13  Med: 0.3 Max: 2.15
Current: 0.3
0.13
2.15
POCF 1.87
BSPM's POCF is ranked higher than
96% of the 249 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.62 vs. BSPM: 1.87 )
Ranked among companies with meaningful POCF only.
BSPM' s POCF Range Over the Past 10 Years
Min: 0.51  Med: 2.86 Max: 19.6
Current: 1.87
0.51
19.6
EV-to-EBIT -0.37
BSPM's EV-to-EBIT is ranked lower than
99.99% of the 523 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.84 vs. BSPM: -0.37 )
Ranked among companies with meaningful EV-to-EBIT only.
BSPM' s EV-to-EBIT Range Over the Past 10 Years
Min: -16.1  Med: 2.3 Max: 58
Current: -0.37
-16.1
58
EV-to-EBITDA -0.41
BSPM's EV-to-EBITDA is ranked lower than
99.99% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.38 vs. BSPM: -0.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
BSPM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.5  Med: 1.7 Max: 21.5
Current: -0.41
-9.5
21.5
Current Ratio 2.37
BSPM's Current Ratio is ranked lower than
51% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. BSPM: 2.37 )
Ranked among companies with meaningful Current Ratio only.
BSPM' s Current Ratio Range Over the Past 10 Years
Min: 1.68  Med: 4.99 Max: 19.49
Current: 2.37
1.68
19.49
Quick Ratio 2.33
BSPM's Quick Ratio is ranked higher than
60% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. BSPM: 2.33 )
Ranked among companies with meaningful Quick Ratio only.
BSPM' s Quick Ratio Range Over the Past 10 Years
Min: 1.63  Med: 4.92 Max: 19.17
Current: 2.33
1.63
19.17
Days Inventory 11.51
BSPM's Days Inventory is ranked higher than
96% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.20 vs. BSPM: 11.51 )
Ranked among companies with meaningful Days Inventory only.
BSPM' s Days Inventory Range Over the Past 10 Years
Min: 6.29  Med: 10.35 Max: 20.81
Current: 11.51
6.29
20.81
Days Sales Outstanding 255.43
BSPM's Days Sales Outstanding is ranked lower than
97% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.29 vs. BSPM: 255.43 )
Ranked among companies with meaningful Days Sales Outstanding only.
BSPM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 94.72  Med: 135.56 Max: 255.43
Current: 255.43
94.72
255.43

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -15.60
BSPM's 3-Year Average Share Buyback Ratio is ranked lower than
78% of the 425 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.60 vs. BSPM: -15.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BSPM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -18.1  Med: -10.55 Max: -8.5
Current: -15.6
-18.1
-8.5

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 0.72
BSPM's Price/Net Current Asset Value is ranked higher than
96% of the 439 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. BSPM: 0.72 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BSPM' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.26  Med: 0.57 Max: 4.3
Current: 0.72
0.26
4.3
Price/Tangible Book 0.17
BSPM's Price/Tangible Book is ranked higher than
98% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. BSPM: 0.17 )
Ranked among companies with meaningful Price/Tangible Book only.
BSPM' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.11  Med: 0.31 Max: 3.48
Current: 0.17
0.11
3.48
Price/Projected FCF 0.08
BSPM's Price/Projected FCF is ranked higher than
99% of the 304 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.53 vs. BSPM: 0.08 )
Ranked among companies with meaningful Price/Projected FCF only.
BSPM' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.05  Med: 0.16 Max: 0.27
Current: 0.08
0.05
0.27
Price/Median PS Value 1.01
BSPM's Price/Median PS Value is ranked lower than
65% of the 653 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.15 vs. BSPM: 1.01 )
Ranked among companies with meaningful Price/Median PS Value only.
BSPM' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.45  Med: 1.05 Max: 6.64
Current: 1.01
0.45
6.64
Earnings Yield (Greenblatt) (%) -270.30
BSPM's Earnings Yield (Greenblatt) (%) is ranked lower than
99% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. BSPM: -270.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BSPM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -270.3  Med: 27.75 Max: 7733
Current: -270.3
-270.3
7733

More Statistics

Revenue (TTM) (Mil) $21.02
EPS (TTM) $ -11.61
Beta2.12
Short Percentage of Float11.29%
52-Week Range $1.08 - 6.59
Shares Outstanding (Mil)2.21
» More Articles for NAS:BSPM

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: ANADIGICS Inc., Biostar Pharmaceuticals Inc., Astrotech Corp. May 30 2011 

More From Other Websites
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Aug 22 2016
4:03 pm Biostar Pharma reports Q2 results; co determines that there is substantial doubt as to its... Aug 22 2016
Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Three Months Ended June 30, 2016 Aug 22 2016
Stocks Coverage on the Healthcare Sector for Biostar Pharma, GlobeImmune, Neuralstem, and GW Pharma Jul 18 2016
BioStar Pharmaceuticals, Inc. :BSPM-US: Earnings Analysis: Q1, 2016 By the Numbers : June 28, 2016 Jun 28 2016
Coverage of Top Gainers on Biostar Pharma, Skullcandy, Finish Line and Electro Rent Jun 27 2016
Why Are These Five Stocks Trending Today? Jun 24 2016
BioStar Pharmaceuticals, Inc.: Gathering momentum, can it sustain its performance? Jun 15 2016
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 13 2016
For These Small Cap Stocks it is All About Massive Growth Jun 09 2016
BIOSTAR PHARMACEUTICALS, INC. Financials May 28 2016
Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Three Months Ended March 31, 2016 May 24 2016
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 23 2016
Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Three Months Ended March 31, 2016 May 23 2016
Biostar Pharmaceuticals, Inc. Announces Its Annual Results for The Year Ended December 31, 2015 Apr 17 2016
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Apr 14 2016
Biostar Pharmaceuticals, Inc. Announces Its Annual Results for The Year Ended December 31, 2015 Apr 14 2016
BIOSTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 24 2016
Biostar Pharmaceuticals Regains Compliance with NASDAQ $1.00 Minimum Bid Price Feb 24 2016
Biostar Pharmaceuticals Airs Advertisements for its Analgesic (Pain Relief) Cream on China's CCTV Feb 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)